Chonluten Research Overview (also known as Ala-Glu-Asp-Leu, Pulmonary bioregulator, Lung tetrapeptide bioregulator)
A tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Khavinson's group for bronchial and alveolar epithelium restoration. Research interest includes chronic respiratory disease, COPD, pulmonary fibrosis, and age-related lung decline.
What Is Chonluten?
Chonluten is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of short peptide bioregulators designed to selectively restore gene expression in specific tissue types — in Chonluten’s case, the bronchial and alveolar epithelium of the lungs.
Khavinson’s group identified that short di- to tetrapeptides derived from tissue-specific organ extracts retain the capacity to interact with complementary DNA sequences and modulate gene transcription relevant to the organ of origin. Chonluten was isolated and synthesized from lung tissue fractions and has been studied primarily in the context of chronic respiratory disease, age-related pulmonary decline, and post-infection lung tissue restoration.
Research use is conducted under RUO (Research Use Only) conditions. Chonluten is not approved as a therapeutic agent in the United States or the European Union.
Mechanism of Action
Chonluten’s proposed mechanism centers on epigenetic and transcriptional regulation within bronchial and alveolar epithelial cells. The tetrapeptide sequence Ala-Glu-Asp-Leu carries a charge distribution that facilitates interaction with histones and promoter regions of genes governing cell cycle regulation, inflammatory signaling, and extracellular matrix maintenance in pulmonary tissue.
Khavinson’s laboratory reported that tetrapeptide bioregulators of this class bind to double-stranded DNA at complementary purine-pyrimidine sequences, functioning as sequence-specific regulators of chromatin structure. In pulmonary cells, Chonluten has been proposed to upregulate genes involved in mucociliary clearance, alveolar surfactant production, and anti-oxidant defenses, while modulating NF-κB-mediated pro-inflammatory cytokine production.
Preclinical data suggest effects on bronchial smooth muscle relaxation and on slowing the fibrotic remodeling pathways implicated in COPD and idiopathic pulmonary fibrosis (IPF). These findings remain preliminary and are derived primarily from Russian institutional research.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
Respiratory Research
COPD Research
Khavinson studies report improved spirometry markers and reduced inflammatory cytokine burden over 20–30 day courses; bronchial epithelial restoration documented in aged rodent models.
Chronic Bronchitis
Histological studies show restoration of bronchial epithelial morphology and improved mucociliary function after Chonluten treatment in animal models.
Fibrotic Pathway Modulation
TGF-β1 pathway modulation observed in rat models; reduced alveolar wall collagen deposition. Human controlled trials are absent.
Age-Related Pulmonary Decline
Respiratory Aging
Positioned as a geroprotective peptide for lung tissue; normalized epithelial proliferation indices in aging animal models observed across multiple Khavinson laboratory studies.
Post-Infection Lung Restoration
Case series from Russian clinical contexts report accelerated normalization of oxygen saturation and reduced residual inflammation following respiratory infections.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Protocol | 1–2 mg | Once daily | SubQ |
| Post-Infection Recovery | 1 mg | Once daily | SubQ |
Peptide Interactions
Both target pulmonary tissue via Khavinson tetrapeptide mechanisms; stacking proposed for broader bronchial and alveolar coverage.
Immune-modulating bioregulator may synergize in post-infection recovery by supporting T-cell reconstitution alongside lung tissue repair.
Immune support bioregulator commonly paired in Russian post-infection multi-peptide recovery protocols.
KPV carries anti-inflammatory effects via MC1R; may provide additive mucosal anti-inflammatory support.
BPC-157 supports systemic tissue healing and angiogenesis; may enhance vascular support to repairing lung tissue.
Reported Research Timeline
01Course 1 (Days 1–20): Initial bronchial epithelial regulatory signaling; subtle improvements in breathlessness at exertion may begin to emerge by end of course.
02Course 2–3 (Month 3–6): Progressive reduction in exacerbation frequency; improved mucociliary clearance and subjective ease of breathing reported over repeated cycles.
03Course 4+ (Month 6–12+): Cumulative geroprotective benefit across pulmonary tissue; longitudinal outcome evaluation recommended after 1–2 years of intermittent use.
Side effects (reported in cited studies): usually minimal at bioregulator doses
Most common (reported in cited studies): mild injection-site erythema; transient soreness
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Generally well-tolerated in preclinical and limited human studies. No significant adverse effects reported in published Khavinson institutional data.
Not a replacement for established COPD therapies. Chonluten is an RUO research compound; do not substitute it for prescribed bronchodilators, inhaled corticosteroids, or other treatments.
Injection-site reactions (mild erythema, transient soreness) possible with SubQ administration. Rotate sites with each injection.
No allergenicity data available in Western literature. Subjects with known peptide hypersensitivity should exercise caution.
Reconstituted solution: use within 30 days when stored at 2–8°C. Discard if solution appears cloudy or particulate.
RUO only. Not for human therapeutic use. Procure from vendors with third-party CoA and sterility testing.
Seek Medical Attention If:
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Severe or unusual symptoms following administration
Always consult a licensed physician before and during use
Respiratory symptoms that worsen rather than improve during a course
Quality Indicators
Verified Marker
Lyophilized Powder Appearance
White to off-white lyophilized powder. Discard any vial with visible discoloration, clumping, or moisture intrusion.
Verified Marker
Certificate of Analysis (CoA)
Third-party HPLC purity ≥98%; mass spectrometry confirming Ala-Glu-Asp-Leu sequence; endotoxin testing ≤2 EU/mg.
Verified Marker
Sterility Testing
Vendor should provide USP-compliant sterility test results for injectable-grade product.
Expected
Reconstituted Solution Clarity
Clear, colorless solution post-reconstitution. Particulates or turbidity indicate degradation or contamination.
Expected
Packaging Integrity
Sealed vial with intact rubber stopper and crimp cap. Reject any vial with compromised seals.
Red Flag
Pre-mixed or ready-to-inject formulations
Injectable bioregulators should be lyophilized powder requiring reconstitution. Pre-mixed liquid formulations indicate substandard manufacturing.
Research Citations
- Peptide regulation of gene expression and protein synthesis in bronchial epithelium
Khavinson VKh, Grigoriev EI, Malinin VV, et al. Bulletin of Experimental Biology and Medicine. 2003. - Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG. Neuroendocrinology Letters. 2003;24(3–4):233–240. - Peptide bioregulators and aging
Khavinson VKh, Anisimov VN. Biogerontology. 2008. - Peptide AEDL alters gene expression in human lung fibroblasts
Ashapkin VV, Kutueva LI, Vanyushin BF, Khavinson VKh. Biochemistry (Moscow). 2021;86(4).
Research Focus
Pulmonary health, Respiratory aging, COPD, Lung tissue restoration, Khavinson bioregulator
Frequently Asked Questions
What should researchers watch for with Chonluten?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Chonluten?
Course 1 (Days 1–20): Initial bronchial epithelial regulatory signaling; subtle improvements in breathlessness at exertion may begin to emerge by end of course.
How is Chonluten typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →